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Abstract
Lynch Syndrome/HNPCC is a syndrome of cancer predisposition linked to inherited mutations of
genes participating in post-replicative DNA mismatch repair (MMR). The spectrum of cancer
associated with Lynch Syndrome includes tumours of the colorectum, endometrium, ovary, upper
gastrointestinal tract and the urothelium although other cancers are rarely described. We describe
a family of Lynch Syndrome with an hMLH1 mutation, that harbours an unusual tumour spectrum
and its diagnostic and management challenges.
Introduction
Lynch cancer family syndrome, also called hereditary
non-polyposis colorectal cancer syndrome (HNPCC), is
an autosomal dominant cancer predisposition disorder
(OMIM: #14500). Lynch Syndrome carriers have an
increased life-time risk of early onset colorectal cancer
(24–80%) [1-3] and in women, endometrial cancer (20–
60%) [1,3-5]. Other recognised cancer risks include: tran-
sitional cell carcinomata of the renal pelvis and ureters,
carcinoma of the stomach, hepatobiliary and small intes-
tinal cancers and ovarian carcinomas. Rarely other cancers
have been described [6,7]. Sets of criteria (the revised
Bethesda and the Amsterdam I and II criteria) for consid-
ering the diagnosis take into account the tumour spec-
trum in individuals and number of affected family
members, age of tumour onset and pathological features
of tumours.
Tumour predisposition in Lynch Syndrome is due to
mutations in mismatch repair (MMR) genes. Though
genes including hMLH1,  hMSH2,  hMSH6,  hPMS2,
hMLH3, hMSH3 and hPMS1, all participate in this proc-
ess, approximately 90% of the germline mutations found
in Lynch Syndrome families involve hMLH1 and hMSH2
[8,9]. More than 450 germline abnormalities of MMR
genes have been described (InSiGHT, http://www.insight-
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group.org). The majority of these mutations are recog-
nized as pathogenic as they result in the expression of
truncated proteins. However, at least 32% of hMLH1
mutations and 18% of hMSH2 mutations, are missense
variants, which cause single amino-acid substitutions and
are often of debatable relevance to pathogenicity [8].
Inactivation of the MMR system in Lynch Syndrome, due
to somatic mutation of the corresponding normal allele,
results in the accumulation of DNA replication errors in
tumours associated with the syndrome. This is demonstra-
ble as variation in the length of repetitive DNA sequences
(microsatellites) in tumour-extracted DNA, a phenome-
non known as microsatellite instability (MSI). Many
Lynch syndrome-associated tumours also manifest loss of
staining of the protein encoded by whichever MMR gene
is mutated, making immunohistochemistry (IHC) of
tumours (often together with microsatellite analysis) a
helpful first step in the evaluation of a possible MMR-defi-
cient tumour. This may be undertaken prior to determin-
ing if mutation searching of MMR genes in germline DNA
is indicated.
The case presented here illustrates unusual phenotypes,
which raise questions regarding optimal surveillance pro-
tocols in this and other Lynch syndrome families.
Case report
A 40-year old Northern European male was first seen in
the genetics clinic in 1994. He had a history of leiomyosa-
rcoma of the thigh at age 36, treated with a compartmen-
tal resection and post-operative radiotherapy and male
breast cancer (stage T2N0M0) for which he had a right
mastectomy. The relevant family history at presentation
was a paternal history of a father (an ex-smoker but non-
drinker) with oesophageal cancer at 47, and a paternal
grandfather and two paternal uncles who had been
affected with colon cancer in their forties (Figure 1).
Initial diagnoses considered included Li Fraumeni syn-
drome [9], which is associated with germline mutations in
the TP53 gene, due to the presence of a sarcoma and breast
cancer in the proband. Mutations in the hMSH2 gene,
which had been recently cloned at that time were also
considered as the paternal branch of the family including
the uncles and grandfather fitted the Amsterdam I criteria.
Full sequencing of the TP53 gene from blood DNA was
uninformative and mutation testing for mismatch repair
Family tree Figure 1
Family tree. The proband is indicated with an arrow. Nine mutation carriers are depicted as affected with cancer.Hereditary Cancer in Clinical Practice 2009, 7:12 http://www.hccpjournal.com/content/7/1/12
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mutations was not available at that time. Subsequently,
BRCA2 was considered a candidate gene because of the
presence of male breast cancer, but no mutations were
found in either BRCA1 or BRCA2 by screening of the full
coding sequences of these genes with dHPLC and large
rearrangement testing by MLPA.
The patient went on to develop two further primaries –
colon cancer at 48 years (a T1 tumour, treated with a sub-
total colectomy) and prostate cancer at 50 years treated
with brachytherapy. In addition, over the next decade the
family history continued to evolve with the development
of cervical adenosquamous carcinoma in his sister, an oli-
godendroglioma in his niece, a further case of colon can-
cer in a cousin and a prostate cancer in the proband's close
relatives (Figure 1). Immunohistochemical studies of his
breast carcinoma and sarcoma showed loss of hMLH1
staining (Figure 2) while hMSH2 and hMSH6 staining
were normal. Staining was not available in the tumours
from his immediate relatives, but an additional 8 cancers
and one adenoma from other known mutation carriers in
a different branch of the same family also showed loss of
hMLH1 staining (data not shown) while hMSH2 and
hMSH6 staining were normal. MSI testing was less exten-
sively available in the family. While a high level of MSI
was demonstrable in the proband's sarcoma (with three
markers D5S346, D17S250, D2S123), it was not evident
in his breast cancer, despite both tumours losing protein
expression. This is likely to be a function of the known
insensitivity of markers optimised for the detection of MSI
in colorectal cancers, being used to try to detect MSI in
other tumour types [10]. MSI was also demonstrated in 5
samples (4 cancers and one adenoma) from other known
carriers in the second branch of the family.
Molecular analysis of the proband's germline DNA identi-
fied a missense variant in the hMLH1  gene (reference
sequence NM_000249.2) in exon 2 at nucleotide position
200 (c.200G>A), which predicts substitution of glycine 67
with a glutamic acid residue (p.Gly67Glu). This putative
p.Gly67Glu mutation segregates with cancer predisposi-
tion in nine family members (see Figure 1). The proband
is currently well and has surveillance with annual sig-
moidoscopy and upper gastrointestinal endoscopy,
annual chest wall examination, 6 monthly and PSA level
measurements and sarcoma follow-up.
Discussion
This case illustrates some of the challenges in assessing
and managing families where Lynch Syndrome is being
considered. In particular, it illustrates the potential for
tumours to arise that are not regarded as classic elements
of the Lynch Syndrome-spectrum and the difficulty in
determining optimal surveillance protocols for such fam-
ilies.
In this family, the identification of two unusual tumours
(male breast cancer and sarcoma) concurrently at a young
age raised the question of Li-Fraumeni syndrome [10] as
these are classic tumours from that spectrum (although
breast cancer in this syndrome is usually seen in females).
Although the family do not fit the classic criteria for the
syndrome, they do meet Li-Fraumeni like criteria [11].
The proband's leiomyosarcoma shows loss of MLH1 staining (right panel) Figure 2
The proband's leiomyosarcoma shows loss of MLH1 staining (right panel). Haematoxylin and Eosin of the section 
(left panel).Hereditary Cancer in Clinical Practice 2009, 7:12 http://www.hccpjournal.com/content/7/1/12
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The fact that the breast cancer occurred in a male proband
who subsequently developed prostate cancer also raised
the possibility of his having an unusual presentation of a
BRCA2  mutation, as lifetime risk (to age 70) of these
tumours is increased to about 7% and 20% respectively
[12-15]. The strength of the family history of colorectal
cancer would not, however, be in keeping with the slight
increases in colorectal risk seen with BRCA mutations;
these are usually seen in those with BRCA1 mutations
rather than BRCA2 [16,17].
The family does, however, fit the revised Amsterdam crite-
ria, which suggests a diagnosis of Lynch Syndrome. The
evidence for pathogenicity of the missense hMLH1 variant
is extensive. It includes the loss of hMLH1 protein staining
in our proband's tumours and in the additional nine
tumours (8 cancers and one adenoma) from his distant
relatives. This loss of hMLH1 staining may be due more to
a loss of antibody-specific epitope rather than an actual
absence of protein expression. The co-segregation of the
variant with disease similarly supports pathogenicity as
does recent in vivo demonstration of microsatellite insta-
bility in a yeast model of this variant [18]. The p.Gly67Glu
mutation is not identified in 1688 unaffected controls
[19]. In addition, in-silico analysis using three phenotype
predictive tools – Align GVGD http://agvgd.iarc.fr/
agvgd_input.php, PolyPhen http://genetics.bwh.har
vard.edu/pph/ and SIFT http://blocks.fhcrc.org/sift/
SIFT.html, all support p.Gly67Glu being pathogenic.
There have been three reported cases of p.Gly67Arg muta-
tions [19,20] which are regarded as pathogenic because
the Gly67 residue is located in the catalytic ATP-binding
pocket of MLH1. This is evolutionarily highly conserved
and essential for its biological function [20]. Tumours
from p.Gly67Arg are often associated with MSI, and this
mutation segregates with disease.
Our proband has been previously mentioned in a report
of Lynch Syndrome variants [18] but we are not aware of
other descriptions of the co-existence of breast tumour,
sarcoma, colorectal cancer and prostate cancer in a single
proband with an hMLH1 mutation. Such tumours have,
however, been reported in isolation in Lynch Syndrome
patients. Soft tissue sarcomas have been described in
Lynch Syndrome families [21,22] and may be associated
with mutations in hMSH2, hMSH6 and MLH1 [22,23].
Male breast cancer has been reported in an hMLH1 carrier
family [7] and the breast cancer risk for women in hMLH1
families has been reported as being increased by Scott et
al. [24] although others have not replicated this [25,26].
Recently, data from Barrow et al. [26] support a possible
moderate increase in these families. Similarly, prostate
cancers have also been reported in Lynch Syndrome kin-
dreds [27,28] but as we do not have staining information
for the prostate tumours (nor for the cervical cancer) in
our family we cannot know if mismatch repair was
involved in their pathogenesis.
Possible explanations for the range of tumours seen in our
patient could include unidentified modifier genes [25]
that have increased his risks, but have not been co-inher-
ited by other hMLH1 mutation carriers in his family. Alter-
natively, it remains possible that there is an effect specific
to mutations at this location as it is noted that the closely
related p.Gly67Trp mutation has also been reported in a
carrier to present with colorectal cancer, brain cancer, lym-
phoma, leukemia and rhabdomyosarcoma [29].
We cannot exclude that the patient's later cancers were
radiation induced; there is scatter dose and so second
tumours can occur both within and outside the radiation
field. Of note, homozygous Mlh1-deficient mice have
increased radiation sensitivity [30] and increased chroma-
tid exchanges have been induced in G2 in lymphocytes
from Lynch Syndrome patients [31].
The glioma in the proband's niece, although rare, is a rec-
ognised element of Lynch Syndrome families, who may
be referred to as having the Turcot variant.
Due to the rarity of such clinical presentations, there are
few data on which to base advice regarding modifications
to the screening regime for hMLH1 carriers in this family.
In addition to surveillance of his gastrointestinal tract
(with annual sigmoidoscopy and gastroscopy (due to his
paternal history of oesophageal cancer), our patient has 6
monthly follow up of his multiple primaries with a gen-
eral physical examination including that of his chest wall,
and PSA levels. He has urinary cytology performed as fol-
low up of an episode of atypia that was attributed to his
prostate therapy but the value of such cytology is debata-
ble given the lack of sensitivity demonstrated by Myrhoj et
al. [32] and may be discontinued.
We have suggested that unaffected carriers are offered two
yearly colonoscopy from 25 and second yearly gastros-
copy from 35 (due to the diagnosis of oesophageal cancer
in the proband's father at age 47) and that women have
gynaecological surveillance with endometrial biopsy from
35 and ultrasound of the ovaries with CA125 as part of the
research programme UKFOCSS (United Kingdom Famil-
ial Ovarian Cancer Screening Study). The screening mod-
ifications based on the cancer history specifically in the
proband have included annual PSA screening from 45
and the advice that male carriers report any changes in
breast tissue early, although it is difficult to know if such
advice is pertinent more widely than within our proband's
immediate relatives.Hereditary Cancer in Clinical Practice 2009, 7:12 http://www.hccpjournal.com/content/7/1/12
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In summary, we describe a family kindred where an
hMLH1 p.Gly67Glu germline mutation is associated with
an unusual presentation of Lynch Syndrome. Identifica-
tion of more families with this pathogenic mutation is
likely to shed light on the mechanism for carcinogenesis
in our kindred.
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